孕三烯酮和米非司酮治疗术后子宫内膜异位症的疗效观察

目的：探讨孕三烯酮和米非司酮治疗术后子宫内膜异位症的临床疗效.方法：82例盆腔子宫内膜异位症手术患者,随机分为孕三烯酮组和米非司酮组,每组41例.孕三烯酮组,按2.5 mg/次,2次/周,口服给药.米非司酮组,按12.5 mg/次,1次/d,口服给药,分析两组患者的疗效.结果：米非司酮组缓解率90.3％,与孕三烯酮组缓解率87.8％比较,差异无统计学意义（P＞0.05）;治疗后米非司酮组血清P（12.96±7.33）nmol/L,与孕三烯酮组血清P（11.88±7.29） nmol/L比较,差异有统计学意义（P＜0.05）;服药期间,米非司酮组出现恶心症状患者6例（14.6％）,明显低于孕三烯酮组21例（51.2％）,差异有统计学意义（P＜0.05）.结论：子宫内膜异位症术后应用米非司酮的治疗效果较孕三烯酮好.

Eeffect of gestrinone and mifepristone in treating postoperative endometriosis

Objective. To investigate the clinical effect of gestrinone and mifepristone on the treatment of postoperative endometriosis. Methods： 82 Cases of pelvic endometriosis were randomized into two groups with 41 cases each. Patients in the gestrinone group were administered orally gestrinone, 2.5rag a time, twice a week; while patients in the mifepristone group were given oral mifepristone, 12.5mg a time, once a day. The treatment effect of both groups were analyzed. Results： The total remission rate was 90.3% and 87.8% in the mifepristone group and the gestrinone group respectively, which was no significant difference （P〈0.05） ; serum P level of the mifepristone group and the gestrinone group after treatment was （12.96±7.33） nmol/L and（11. 88±7.29） nmol/L respectively, which was of statistical difference （P〈0.05）; during medications, nausea symptoms of 6 cases （14.6%） occurred in the mifepristone group, which was lower than that in the gestrinone group （51.2%）, there was statistical difference between both group （P〈0.05）. Conclusion： The postoperative application of mifepristone to treating endometriosis can gain better effect than gestrinone.